Regula Deurloo
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Cancer Research top 10%
- Cancer, Hypoxia, and Metabolism
Papers in
- Oncology 11
- Cancer Immunotherapy and Biomarkers 8
- Cancer Treatment and Pharmacology 4
- HER2/EGFR in Cancer Research 4
- Colorectal Cancer Treatments and Studies 1
-
- Advanced Breast Cancer Therapies 4
- Brain Metastases and Treatment 1
- Co-authors
- Alan B. Sandler (1 shared paper)Herbert I. Hurwitz (1 shared paper)Robert L. Coleman (1 shared paper)David Miles (1 shared paper)Josep Garcia (1 shared paper)Olivier Chinot (1 shared paper)Giuseppe Viale (2 shared papers)Kalliopi P. Siziopikou (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)Cancer Research (2 papers)Cancers (1 paper)JNCI Journal of the National Cancer Institute (1 paper)Future Oncology (1 paper)
- Partner nations
- SwitzerlandGermanyUnited Kingdom
In The Last Decade
Regula Deurloo
12 papers receiving 941 citations
Regula Deurloo's Hit Papers
Peers
Comparison fields: 5 of 87
- Oncology 468
- Cancer Research 222
- Immunology 153
- Hepatology 53
- Pulmonary and Respiratory Medicine 215
Countries citing papers authored by Regula Deurloo
This map shows the geographic impact of Regula Deurloo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Regula Deurloo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Regula Deurloo more than expected).
Fields of papers citing papers by Regula Deurloo
This network shows the impact of papers produced by Regula Deurloo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Regula Deurloo. The network helps show where Regula Deurloo may publish in the future.
Co-authors
The 25 scholars most cited alongside Regula Deurloo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook Hit paper breakdown → | 2020 | 780 |
| 2 | 2019 | 57 | |
| 3 | 2021 | 45 | |
| 4 | 2023 | 40 | |
| 5 | 2021 | 10 | |
| 6 | 2022 | 4 | |
| 7 | 2024 | 3 | |
| 8 | 2021 | 3 | |
| 9 | 2016 | 2 | |
| 10 | 2018 | 1 | |
| 11 | 2022 | 1 | |
| 12 | 2015 | 1 |
About Regula Deurloo
Regula Deurloo is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Pathology and Forensic Medicine, having authored 12 papers that have together received 947 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (8 papers), Cancer Treatment and Pharmacology (4 papers), HER2/EGFR in Cancer Research (4 papers), Advanced Breast Cancer Therapies (4 papers), Cancer Genomics and Diagnostics (2 papers), Brain Metastases and Treatment (1 paper), Colorectal Cancer Treatments and Studies (1 paper) and Breast Cancer Treatment Studies (1 paper). The work is most often cited by research in Oncology (468 citations), Cancer Research (222 citations), Immunology (153 citations), Hepatology (53 citations) and Pulmonary and Respiratory Medicine (215 citations). Regula Deurloo has collaborated with scholars based in Switzerland, Germany and United Kingdom. Frequent co-authors include Alan B. Sandler, Herbert I. Hurwitz, Robert L. Coleman, David Miles, Josep Garcia, Olivier Chinot, Giuseppe Viale, Kalliopi P. Siziopikou, Corrado D’Arrigo and Frédérique Penault‐Llorca. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Cancers, JNCI Journal of the National Cancer Institute and Future Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.